Fig. 2.
Fig. 2. Time course and titration of STI571. / (A) CD34-enriched cells derived from 5 patients with chronic-phase CML were used to establish cultures in the presence (+GF) or absence (−GF) of GFs in SFM (see “Materials and methods”). STI571 was added on day 0 only, at concentrations ranging from 0 to 10 μM, as shown in the legend. On days 3, 6, and 12, triplicate wells for each condition were harvested, and viable cell counts were performed. Results represent the mean viable cell number ± SEM of triplicate measurements performed for each of 5 patient samples. (B) Recovery (compared with control) on days 3, 6, and 12 of cells cultured in the presence of STI571 at 1 μM (similar trend for 5 and 10 μM) and in the presence or the absence of growth factors.

Time course and titration of STI571.

(A) CD34-enriched cells derived from 5 patients with chronic-phase CML were used to establish cultures in the presence (+GF) or absence (−GF) of GFs in SFM (see “Materials and methods”). STI571 was added on day 0 only, at concentrations ranging from 0 to 10 μM, as shown in the legend. On days 3, 6, and 12, triplicate wells for each condition were harvested, and viable cell counts were performed. Results represent the mean viable cell number ± SEM of triplicate measurements performed for each of 5 patient samples. (B) Recovery (compared with control) on days 3, 6, and 12 of cells cultured in the presence of STI571 at 1 μM (similar trend for 5 and 10 μM) and in the presence or the absence of growth factors.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal